Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Xpeng Inc - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Xpeng Inc - ADR trades at $12.95 (market cap $12.50B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.2× Xpeng Inc - ADR's market cap. Which is the better fit depends on your goals.
| ALNY | XPEV | |
|---|---|---|
Market Cap | $39.89B | $12.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $28.07 |
52-Week Low | $278.09 | $12.09 |
Enterprise Value | $38.15B | $14.62B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XPEV trades at $13.03, up 0.39% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 revenue of $73.9B but a net loss of $2.3B, continuing negative profitability trends. Recent news highlights include Robotaxi testing and European market expansion, while analyst consensus remains 64.7% buy despite cash flow challenges.
Outlook is mixed: growth in autonomous driving and international markets offers upside, but persistent losses and competitive pressures pose significant risks. Investors should weigh innovation potential against financial sustainability in the volatile EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
